Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Thursday, March 31, 2022.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q1 FY2022 (2022-03-31): -550.52%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
N/A
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$533.04M
Return on Equity (ROE)
-13.64%
TTM Avg
-19.13%
3Y Avg
-73.22%
5Y Avg
-63.52%
Market Cap
$531.98M
Return on Equity (ROE)
0.44%
TTM Avg
-17.98%
3Y Avg
71.24%
5Y Avg
-6.51%
Market Cap
$531.52M
Return on Equity (ROE)
-306.61%
TTM Avg
-169.61%
3Y Avg
-163.97%
5Y Avg
-73.13%
Market Cap
$529.58M
Return on Equity (ROE)
-24.90%
TTM Avg
-76.97%
3Y Avg
-68.04%
5Y Avg
-50.09%
Market Cap
$548.51M
Return on Equity (ROE)
N/A
TTM Avg
91.17%
3Y Avg
180.92%
5Y Avg
76.31%
Market Cap
$524.43M
Return on Equity (ROE)
-17.44%
TTM Avg
-97.25%
3Y Avg
-87.77%
5Y Avg
-77.06%
Market Cap
$519.25M
Return on Equity (ROE)
-19.35%
TTM Avg
-58.07%
3Y Avg
-51.86%
5Y Avg
-46.32%
Market Cap
$557.32M
Return on Equity (ROE)
-26.37%
TTM Avg
-3503.18%
3Y Avg
-1722.33%
5Y Avg
3198.08%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ProKidney Corp. (PROK) | $538.01M | N/A | N/A | N/A | N/A |
| Monopar Therapeutics Inc. (MNPR)vs › | $533.04M | -13.64% | -19.13% | -73.22% | -63.52% |
| Delcath Systems, Inc. (DCTH)vs › | $531.98M | 0.44% | -17.98% | 71.24% | -6.51% |
| Nuvectis Pharma, Inc. (NVCT)vs › | $531.52M | -306.61% | -169.61% | -163.97% | -73.13% |
| Shattuck Labs, Inc. (STTK)vs › | $529.58M | -24.90% | -76.97% | -68.04% | -50.09% |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $548.51M | N/A | 91.17% | 180.92% | 76.31% |
| Immix Biopharma, Inc. (IMMX)vs › | $524.43M | -17.44% | -97.25% | -87.77% | -77.06% |
| Altimmune, Inc. (ALT)vs › | $519.25M | -19.35% | -58.07% | -51.86% | -46.32% |
| CytomX Therapeutics, Inc. (CTMX)vs › | $557.32M | -26.37% | -3503.18% | -1722.33% | 3198.08% |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $516.76M | -60.79% | -73.94% | -62.04% | -71.62% |
ROE
N/A
ROA
-34.8%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2022-03-31 | -550.52% |
| 2021-12-31 | -204.87% |
| 2021-09-30 | -471.47% |
